Is compounded semaglutide or tirzepatide legal and safe in 2026?
What compounding is, why the shortage rules ended, the FDA’s warning letters and adverse event reports, and how to check what you are being sold. In the FDA’s own words.
Written for the United States, from US sources.
Compounded semaglutide and tirzepatide are not FDA-approved: the FDA doesn’t check their safety, effectiveness or quality. Both shortages ended in 2025, so pharmacies can no longer routinely make copies of the brands. The FDA had logged 990 adverse event reports for compounded semaglutide and over 730 for tirzepatide by May 2026.
Key takeaways
- Compounded GLP‑1 drugs are not FDA-approved, which means the FDA does not review their safety, effectiveness or quality before they are sold.1
- The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, ending the period when compounders could copy the brands.2
- Firms may not call compounded GLP‑1s generic, the same as an approved drug, or clinically proven, the FDA said in February 2026.3
- By May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide.4
- In April 2026 the FDA proposed barring outsourcing facilities from compounding semaglutide, tirzepatide and liraglutide from bulk powder; we found no final decision by October 12, 2026.5
- We don’t recommend compounded GLP‑1s, list their prices or name any seller. This post explains the FDA’s position in its own words.
- FDA-approved versions are sold at published cash prices: see GLP‑1 costs without insurance.
- Any GLP‑1 needs a prescription. A prescriber decides what fits you.
On this page
What is a compounded GLP‑1?
It is a version mixed by a pharmacy rather than made by the drug’s maker, and it has not been through the FDA’s approval review.1
Compounding is when a pharmacist combines or alters ingredients to make a medicine for a patient. The law has two kinds of compounder:
- 503A pharmacies: state-licensed pharmacies that compound for individual prescriptions.2
- 503B outsourcing facilities: larger operations registered with the FDA that can make batches.2
In the FDA’s words: “Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed. Compounded drugs are also not the same as generic drugs.”1 A generic is FDA-approved; a compounded drug is not.
The FDA also warns about salt forms, such as semaglutide sodium and semaglutide acetate. These are “different active ingredients than are used in the approved drugs”.4
Is compounded semaglutide or tirzepatide still legal?
Only narrowly: since the shortages ended in 2025, pharmacies may not routinely make copies of the approved brands, unless a prescriber documents a significant difference for that patient.2
During a shortage, compounders may make copies of a drug. The FDA ended its shortage listings and then its grace periods:2
- Dec 19, 2024Tirzepatide shortage declared resolved. Grace period ended Feb 18, 2025, for 503A pharmacies and Mar 19, 2025, for 503B facilities.
- Feb 21, 2025Semaglutide shortage declared resolved. Grace period ended Apr 22, 2025, for 503A and May 22, 2025, for 503B.
- Apr 30, 2026The FDA proposed leaving all three GLP‑1s off the list of bulk substances 503B facilities may use. The comment period was extended and closed on July 30, 2026.5
Now, a 503A pharmacy may not compound “essentially copies” of an available approved drug regularly or in large amounts. The exception is when a prescriber documents a significant difference for that particular patient.2
FDA Commissioner Marty Makary said that when approved drugs are available, outsourcing facilities “cannot lawfully compound using bulk drug substances unless there is a clear clinical need”.5 We found no final decision on the April proposal as of October 12, 2026.
What has the FDA done about it?
It has warned dozens of telehealth companies over misleading claims and said it will restrict the ingredients used in mass-marketed compounded GLP‑1s.1,3
February 6, 2026: the FDA said it intends to restrict GLP‑1 active ingredients meant for compounded drugs “that are being mass-marketed by companies”.3 It said firms cannot claim their products are:
- “generic versions or the same as drugs approved by FDA”;
- made with “the same active ingredient as the FDA-approved drugs”;
- “clinically proven to produce results”.3
March 3, 2026: the FDA sent warning letters to 30 telehealth companies.1 It said they implied their products were the same as approved drugs. Some also sold compounded drugs under their own brand names without saying who made them.1
Why the marketing exists at all: compounded versions were sold during the shortages, when the brands were hard to get. The brands’ own cash prices have since fallen: see GLP‑1 costs without insurance.
Build your own list of questions to take to your doctor. No sign-up.
Is compounded semaglutide safe?
The FDA can’t say, because it hasn’t reviewed these products; it has received hundreds of adverse event reports and reports of dosing errors.4
An adverse event report is a report of a problem after use, sent to the FDA by a patient, clinician or company. The FDA also describes dosing errors with compounded injectable semaglutide.4 Some came from patients measuring their own doses from vials. Others came from clinicians miscalculating, and some patients got doses beyond those in the approved label.4
The approved medicines carry their own risks, set out in their labels. Those labels don’t vouch for a compounded product, because nobody has checked that it contains what it says.
How can you tell what you’re being offered?
Ask whether the product is the FDA-approved brand or a compounded drug, and check the pharmacy’s state license; the FDA lists the signs of an unsafe seller.4,8
The FDA advises getting a prescription from a licensed prescriber and filling it at a state-licensed pharmacy.4 Its signs of an unsafe online pharmacy include ones that:8
- “Do not require a doctor’s prescription”;
- “Are not licensed in the U.S. and by your state board of pharmacy”;
- “Offer deep discounts or prices that seem too good to be true”;
- “Send medicine that looks different than what you receive at your usual pharmacy”.
Watch the wording too. A seller saying its product is “the same as” Wegovy, “generic” or “clinically proven” is making claims the FDA says are not allowed.3 If you already have a multi-dose vial, the FDA says to throw it away 28 days after first use.4
Telehealth memberships and their hidden costs are covered in GLP‑1 telehealth. Fake pens of the real brands are a separate problem: see counterfeit Ozempic in the US.
Questions people ask
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It is not FDA-approved, and the FDA says firms may not claim it is the same as, or a generic of, an approved drug. Some versions use salt forms that are different active ingredients.3,4
Is compounded tirzepatide legal?
Only narrowly. The tirzepatide shortage ended in December 2024 and the grace periods ended in early 2025. A pharmacy may not routinely copy Zepbound or Mounjaro unless a prescriber documents a significant difference for that patient.2
Is compounded semaglutide a generic?
No. A generic is FDA-approved. The FDA says compounded drugs “are also not the same as generic drugs”.1
Why did the FDA send warning letters to telehealth companies?
In March 2026 it warned 30 companies for implying their compounded products were the same as approved drugs and for selling them under their own brand names without saying who made them.1
How do I report a problem with a compounded GLP‑1?
Use the FDA’s MedWatch program online or call 1-800-FDA-1088.9,10
How we researched this
Everything here comes from FDA statements, press releases and its compounding policy page, checked on October 12, 2026, plus a named trade report of the April 2026 proposal.4,3,1,2,5
We name no compounder, pharmacy or telehealth company, and quote no compounded prices. Federal and state rules in this area are changing; check the FDA’s page for the latest.
Before you move on
- Ask: is this the FDA-approved brand or compounded?
- Check the pharmacy’s license with your state board.
- Be wary of “same as”, “generic” or “clinically proven”.
- Throw out a multi-dose vial 28 days after first use.
- Report problems to MedWatch.
More from the US blog
The monthly US update
An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: FDA approvals and warnings, Medicare and Medicaid changes, and makers’ price changes. How we write
Sources
- FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press release, March 3, 2026. Link
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of April 1, 2026. Link
- FDA. FDA intends to take action against non-FDA-approved GLP-1 drugs. Statement, February 6, 2026. Link
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. Link
- Drug Topics. FDA proposes to exclude GLP-1s from 503B bulks list. May 13, 2026. Link
- Poison Control (National Capital Poison Center). Poison help line 1-800-222-1222. Link
- Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information. Revised 06/2026. Link
- FDA. How to buy medicines safely from an online pharmacy. Consumer update, January 2, 2025. Link
- FDA. MedWatch: the FDA safety information and adverse event reporting program. Link
- Eli Lilly. Zepbound (tirzepatide): US prescribing information. Revised 8/2026. Link
Last checked Oct 12, 2026 · Next review due Apr 12, 2027 · Report an error
How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your doctor, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write